What is the recommended management for hepatic steatosis (non‑alcoholic fatty liver disease)?

Management of Hepatic Steatosis (Non-Alcoholic Fatty Liver Disease)

Lifestyle modification targeting 7–10% total body weight loss through a Mediterranean diet and vigorous-intensity exercise is the only proven first-line treatment for all patients with hepatic steatosis; pharmacologic therapy is reserved exclusively for biopsy-proven NASH with significant fibrosis (≥F2). 1, 2, 3

---

Risk Stratification Determines Treatment Intensity

Initial Assessment

• Calculate the FIB-4 score using age, AST, ALT, and platelet count as the first-line risk stratification tool 2
• In patients >65 years, a FIB-4 <2.0 effectively rules out advanced fibrosis; manage in primary care with lifestyle measures and repeat assessment in 2–3 years 2
• A FIB-4 >2.67 or liver stiffness ≥12 kPa on transient elastography indicates high probability of advanced fibrosis and mandates immediate hepatology referral 1, 2
• Patients with low risk (FIB-4 <1.3, LSM <8.0 kPa, or F0-F1 fibrosis) should focus exclusively on lifestyle interventions without pharmacotherapy 1, 2

When to Perform Liver Biopsy

• Reserve biopsy for patients with diabetes or metabolic syndrome, FIB-4 >2.67, liver stiffness >12 kPa, or clinical features suggesting cirrhosis (thrombocytopenia, AST>ALT, hypoalbuminemia) 4, 2
• Biopsy is required when non-invasive tests are discordant or when considering pharmacologic therapy for biopsy-proven NASH with ≥F2 fibrosis 4, 2

---

Lifestyle Interventions: The Cornerstone of Treatment

Weight-Loss Targets and Expected Outcomes

• 3–5% weight loss improves steatosis 4, 1
• 7% weight loss achieves NASH resolution in approximately 64% of patients 1, 3
• ≥10% weight loss results in fibrosis regression in 45% and stabilization in the remaining 55% 1, 2, 3
• Weight loss must be gradual (≤1 kg/week); rapid loss >1 kg/week can worsen portal inflammation, exacerbate fibrosis, or precipitate acute hepatic failure 1, 3

Dietary Prescription

• Adopt a Mediterranean dietary pattern (high in vegetables, fruits, whole grains, legumes, olive oil, fish; low in red meat and processed foods), which reduces hepatic fat even without weight loss 1, 2, 3
• Create a daily caloric deficit of 500–1000 kcal (approximately 1200–1500 kcal/day for women; 1500–1800 kcal/day for men) 1, 3
• Completely eliminate fructose-containing beverages and sugar-sweetened drinks 1, 3

Exercise Prescription

• Vigorous-intensity aerobic exercise (≥6 METs) for 75–150 minutes per week is required to improve NASH severity and fibrosis; moderate-intensity exercise alone does not improve fibrosis 2, 3
• Alternatively, 150–300 minutes per week of moderate-intensity exercise reduces hepatic steatosis and improves liver enzymes even without significant weight loss 1, 2
• Add resistance training ≥2 days/week to preserve lean muscle mass and augment metabolic benefits 2, 3

Alcohol Guidance

• Limit alcohol to ≤30 g/day for men and ≤20 g/day for women in pre-cirrhotic disease 1, 3
• Complete abstinence is mandatory in NASH-related cirrhosis to reduce hepatocellular carcinoma risk 1, 2, 3

---

Management of Metabolic Comorbidities

Diabetes Management

• GLP-1 receptor agonists (semaglutide, liraglutide) are preferred first-line agents for patients with type 2 diabetes and NAFLD because they improve both glycemic control and liver histology 1, 2, 3
• Avoid sulfonylureas and insulin when possible, as they are associated with 1.6-fold and 2.6-fold increased hepatocellular carcinoma risk, respectively 1, 2

Dyslipidemia Management

• Statins are safe and strongly recommended for all NAFLD patients with dyslipidemia; they reduce hepatocellular carcinoma risk by 37% and hepatic decompensation by 46% 1, 2, 3

Cardiovascular Risk

• Cardiovascular disease, not liver disease, is the leading cause of death in NAFLD patients without cirrhosis; aggressive treatment of all metabolic syndrome components is mandatory 1, 3

---

Pharmacologic Treatment for Advanced Disease (Biopsy-Proven NASH with ≥F2 Fibrosis)

First-Line Pharmacologic Agents

• Resmetirom is the preferred agent where approved, showing histologic improvement in steatohepatitis and fibrosis with an acceptable safety profile 2, 5
• Semaglutide 0.4 mg daily achieved NASH resolution without fibrosis worsening in 59% of treated patients versus 17% with placebo 2, 3

Alternative Agents

• Pioglitazone 30 mg daily increases odds of NASH resolution (OR ≈3.2) and advanced fibrosis reversal (OR ≈3.1); modest weight gain (~2–3%) can be mitigated with concomitant GLP-1 agonist or SGLT2 inhibitor 2, 3
• Vitamin E 800 IU daily improves steatohepatitis in non-diabetic, non-cirrhotic patients with biopsy-proven NASH 4, 2, 3

Agents NOT Recommended

• Metformin does not produce clinically meaningful improvement in steatohepatitis histology and should not be used as a specific NAFLD treatment 4, 1, 2

---

Bariatric Surgery

• Consider bariatric surgery for patients with BMI ≥35 kg/m² (or ≥40 kg/m²) who have clinically significant fibrosis and have failed lifestyle measures 1, 2, 3
• Surgery achieves histologic NASH resolution in approximately 85% of patients at one year and provides durable improvement in liver histology 2, 3
• Safety and efficacy have not been established in patients with cirrhosis or very high BMI with advanced fibrosis 3

---

Surveillance and Monitoring Strategy

Low-Risk Patients (F0-F1)

• Annual follow-up with repeated non-invasive tests (FIB-4, transient elastography) 1, 2
• Periodic monitoring of serum transaminases (ALT, AST) every 6–12 months 2, 3

High-Risk Patients (≥F2 Fibrosis)

• Refer to hepatology for multidisciplinary care and close follow-up every 6 months 1, 2
• Use transient elastography with CAP and liver stiffness measurements to gauge therapeutic response 2

Cirrhosis (F4)

• Abdominal ultrasound every 6 months for hepatocellular carcinoma surveillance; annual HCC incidence in NASH cirrhosis is 2–3% 1, 2, 3
• Screening endoscopy for esophageal varices at the time of cirrhosis diagnosis 1, 2
• Liver stiffness ≥20 kPa or thrombocytopenia mandates variceal screening 2
• Refer for liver transplantation when clinical criteria are met 2, 3

---

Critical Pitfalls to Avoid

• Do not pursue rapid weight loss >1 kg/week, as it may precipitate hepatic decompensation or worsen fibrosis 1, 3
• Do not withhold statins due to unfounded hepatotoxicity concerns; they are both safe and hepatoprotective 1, 2, 3
• Do not prescribe pharmacologic therapy for simple steatosis without biopsy-proven NASH and significant fibrosis (≥F2) 1, 2, 3
• Do not assume normal ALT excludes advanced fibrosis; approximately 25% of MASLD patients with advanced fibrosis have persistently normal aminotransferases 2
• Do not rely on standard FIB-4 cutoff of 1.3 in patients >65 years; use a threshold of 2.0 to improve specificity 2
• Isolated steatosis is not necessarily benign; if metabolic risk factors persist or deteriorate during follow-up, consider repeat non-invasive assessment or liver biopsy 6